Search company, investor...

Predict your next investment

Bausch Health company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
bauschhealth.com

Portfolio Exits

13

Partners & Customers

10

About Bausch Health

Bausch Health (NYSE/TSX: BHC) s a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.

Headquarters Location

2150 St. Elzear Blvd. West

Laval, Quebec, H7L 4A8,

Canada

800-361-1448

Want to inform investors similar to Bausch Health about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Bausch Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bausch Health in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

Latest Bausch Health News

Global Acne Treatment Market Size to Reach USD 13.59 Billion in 2030 | Emergen Research

Sep 20, 2023

Strategic Development On 5 January 2022,     Galderma S.A. completed its acquisition of ALASTIN Skincare, Inc. after receiving an antitrust clearance from federal authorities of the U.S. Increasing consumer interest and growing popularity of aesthetic skin care procedures had led to a rise in demand for effective products and robust portfolio of ALASTIN and experience in scientific skincare products will increase ability of Galderma to serve a wide range of customers. On 19 December 2019, Ortho Dermatologics (Bausch Health Companies Inc.), a U.S.-based largest prescription dermatology health care business received approval from the U.S. Food and Drug Administration (FDA) for its new drug application for ARAZLO Lotion, 0.045%, for topical treatment of acne vulgaris for patients 9 years and older. It is the first tazarotene acne treatment available in a form of lotion and has proved to be highly effective for treating acne Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/1135 Some Key Highlights from the Report On 24 February 2020, Almirall, S.A, announced to send its product Seysara (sarecycline) to the Chinese regulatory body NMPA in 2023 for approval. It is an innovative tetracycline-derived oral antibiotic used for treatment of inflammatory lesions of moderate to severe acne vulgaris. Almirall S.A has commercialization rights for this product in the U.S., and under a License Agreement from Paratek Pharmaceuticals, Inc., it will develop, register, and commercialize the product in China in exchange for royalties. The antibiotics segment revenue is expected to account for largest revenue share over the forecast period owing to its increasing popularity among people suffering from acne due to its effectiveness. In addition, increasing launch of new antibiotics are more effective due to an increase in antibiotic resistance among patients. The topical segment accounted for a larger revenue share in 2021 owing to growing popularity of Over-the-Counter (OTC) drugs and rapid development of new topical therapy for treatment of acne. Additionally, an increasing number of new discoveries of topical therapy for acne patients will further contribute to revenue growth of the segment. The skincare clinics segment is expected to register a rapid growth rate over the forecast period. High psychological burden associated with acne and increasing demand for hormonal therapy for acne treatment is expected to sustain revenue growth of the market over the forecast period. Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends @ https://www.emergenresearch.com/industry-report/acne-treatment-market Emergen Research has segmented the global acne treatment market based on product, administration, end user, and region: Product Outlook (Revenue, USD Billion, 2019–2030) Retinoids Curated Reports You Shouldn't Miss: Dive In Now! Cell-Free DNA (cfDNA) Testing Market By Type (Cell-free fetal DNA (NIPT), Circulating tumor DNA, Donor-derived cell-free DNA), By Technology (MPSS, t-MPS, SNP, Others), Application (Transplantation, Gynecology, Oncology), By Region Forecasts to 2027 Peritoneal Dialysis Market By Product (Peritoneal Dialysis Solution, Peritoneal Dialysis Set, Device, Catheter), By Type (CAPD, APD), By End-User (Home-Based Dialysis, Dialysis Center & Hospital Based Dialysis) and Regions Forecasts to 2027 Breath Analyzer Market , By Technology (Fuel Cells, Semiconductor Oxide Sensors, and Other Technologies), By Application (Alcohol Detection, Drug Abuse Detection, and Medical Applications), By End-Use, and By Region Forecast to 2032 Assisted Reproductive Technology (ART) Market Size, Share, Trends, By Procedure, By Technology, By End-use, and By Region Forecast to 2028 Rehabilitation Robotics Market By Type (Therapeutic, Exoskeleton, Assistive, Others), By Body Part (Lower Extremity, Upper extremity), By Therapy (Balance, Gait, Limb Mobility), By Application (Neurology, Orthopedics, Others), By Region Forecasts to 2027 About Emergen Research Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. Contact Us:

Bausch Health Portfolio Exits

13 Portfolio Exits

Bausch Health has 13 portfolio exits. Their latest portfolio exit was Bausch & Lomb UK on May 06, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/6/2022

IPO

$99M

Public

5

3/31/2021

Acquired - II

$99M

4

9/4/2019

Acquired - II

$99M

6

5/24/2018

Acquired - II

Subscribe to see more

$99M

Subscribe to see more

10

11/10/2017

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/6/2022

3/31/2021

9/4/2019

5/24/2018

11/10/2017

Exit

IPO

Acquired - II

Acquired - II

Acquired - II

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

4

6

10

10

Bausch Health Acquisitions

19 Acquisitions

Bausch Health acquired 19 companies. Their latest acquisition was Synergetics USA on September 02, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/2/2015

$99M

Acquired

1

8/20/2015

Convertible Note

$99M

$145.01M

Acquired

1

7/23/2015

$99M

Acquired Unit

1

7/17/2015

Subscribe to see more

$99M

Subscribe to see more

10

4/1/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/2/2015

8/20/2015

7/23/2015

7/17/2015

4/1/2015

Investment Stage

Convertible Note

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$145.01M

Note

Acquired

Acquired

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Bausch Health Partners & Customers

10 Partners and customers

Bausch Health has 10 strategic partners and customers. Bausch Health recently partnered with TerraCycle on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/27/2021

Partner

United States

1

9/14/2021

Vendor

United States

Anaqua Delivers Enhanced IP Management to Bausch Health

Anaqua , the leading innovation and intellectual property management technology provider , announced that Bausch Health Companies Inc. has selected Anaqua 's AQX platform to deliver enhanced IP management across the health care products company 's global operations .

2

5/17/2021

Supplier

Italy

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

`` SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health , '' Gilberto Dalesio , SIFI 's CCO , said in a company news release .

3

10/12/2020

Licensor

United States

Subscribe to see more

Subscribe to see more

10

8/6/2018

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

10/27/2021

9/14/2021

5/17/2021

10/12/2020

8/6/2018

Type

Partner

Vendor

Supplier

Licensor

Licensor

Business Partner

Country

United States

United States

Italy

United States

United States

News Snippet

Anaqua Delivers Enhanced IP Management to Bausch Health

Anaqua , the leading innovation and intellectual property management technology provider , announced that Bausch Health Companies Inc. has selected Anaqua 's AQX platform to deliver enhanced IP management across the health care products company 's global operations .

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

`` SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health , '' Gilberto Dalesio , SIFI 's CCO , said in a company news release .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

3

10

10

Bausch Health Team

21 Team Members

Bausch Health has 21 team members, including current Chief Compliance Officer, Senior Vice President, Seana Carson.

Name

Work History

Title

Status

Seana Carson

Chief Compliance Officer, Senior Vice President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Seana Carson

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Compliance Officer, Senior Vice President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.